BRCA2 and pachyonychia congenita: However, within high-risk populations (lifetime risk of 5% or more), including those with familial PC or mutations in a PC predisposition gene (e.g., BRCA2), new onset diabetes, and chronic pancreatitis, screening is proposed to improve patient outcomes while remaining cost effective [11,12,13].